Improved assessment of laser-induced choroidal neovascularization

Microvascular Research

Volumn 80, Issue 3, 2010, Pages 295-302

  Toma, Hassanain S ^a   Barnett, Joshua M ^b   Penn, John S ^a,b   Kim, Stephen J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age related macular degeneration; AMD; Choroidal neovascularization; CNV; Laser induced CNV

Indexed keywords

KETOROLAC; SODIUM CHLORIDE; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRUCH MEMBRANE; COMPUTER ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE SEVERITY; HISTOPATHOLOGY; IMAGING SYSTEM; LASER; NONHUMAN; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; RAT; RELIABILITY; RETINA FLUORESCEIN ANGIOGRAPHY; SUBRETINAL NEOVASCULARIZATION; VALIDITY;

ANIMALS; BRUCH MEMBRANE; CHOROIDAL NEOVASCULARIZATION; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INTRAVITREAL INJECTIONS; KETOROLAC; LASERS, GAS; MALE; MICROSCOPY, FLUORESCENCE; RATS; RATS, INBRED BN; REPRODUCIBILITY OF RESULTS; SOFTWARE; SPECIMEN HANDLING; TIME FACTORS; TRIAMCINOLONE ACETONIDE;

RATTUS NORVEGICUS;

EID: 78249250245     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2010.05.011     Document Type: Article

References (50)

1. Ambati J., Anand A., Fernandez S., Sakurai E., Lynn B.C., Kuziel W.A., Rollins B.J., Ambati B.K. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat. Med. 2003, 9:1390-1397.
2. Arias L., Caminal J.M., Casas L., Masuet C., Badia M.B., Rubio M., Pujol O., Arruga J. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br. J. Ophthalmol. 2008, 92:1636-1641.
3. Baranano D.E., Kim S.J., Edelhauser H.F., Durairaj C., Kompella U.B., Handa J.T. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br. J. Ophthalmol. 2009, 93:1387-1390.
4. Bora P.S., Sohn J.H., Cruz J.M., Jha P., Nishihori H., Wang Y., Kaliappan S., Kaplan H.J., Bora N.S. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J. Immunol. 2005, 174:491-497.
5. Campa C., Kasman I., Ye W., Lee W.P., Fuh G., Ferrara N. Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. Invest. Ophthalmol. Vis. Sci. 2008, 49:1178-1183.
6. Campos M., Amaral J., Becerra S.P., Fariss R.N. A novel imaging technique for experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2006, 47:5163-5170.
7. Castro M.R., Lutz D., Edelman J.L. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp. Eye Res. 2004, 79:275-285.
8. Chakravarthy U., Walsh A.C., Muldrew A., Updike P.G., Barbour T., Sadda S.R. Quantitative fluorescein angiographic analysis of choroidal neovascular membranes: validation and correlation with visual function. Invest. Ophthalmol. Vis. Sci. 2007, 48:349-354.
9. Chan C.C., Ross R.J., Shen D., Ding X., Majumdar Z., Bojanowski C.M., Zhou M., Salem N., Bonner R., Tuo J. Ccl2/Cx3cr1-deficient mice: an animal model for age-related macular degeneration. Ophthalmic Res. 2008, 40:124-128.
10. Ciulla T.A., Criswell M.H., Danis R.P., Hill T.E. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch. Ophthalmol. 2001, 119:399-404.
11. Clarkson J.G., Altman R.D. Angioid streaks. Surv. Ophthalmol. 1982, 26:235-246.
12. Criswell M.H., Hu W.Z., Steffens T.J., Li R., Margaron P. Comparing pegaptanib and triamcinolone efficacy in the rat choroidal neovascularization model. Arch. Ophthalmol. 2008, 126:946-952.
13. Dobi E.T., Puliafito C.A., Destro M. A new model of experimental choroidal neovascularization in the rat. Arch. Ophthalmol. 1989, 107:264-269.
14. Dollery C.T., Hodge J.V., Engel M. Studies of the retinal circulation with flourescein. Br. Med. J. 1962, 2:1210-1215.
15. Edelman J.L., Castro M.R. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp. Eye Res. 2000, 71:523-533.
16. Essex R.W., Qureshi S.H., Cain M.S., Harper C.A., Guymer R.H. Photodynamic therapy in practice: a review of the results of the first 12months experience with verteporfin at the Royal Victorian Eye and Ear Hospital. Clin. Exp. Ophthalmol. 2003, 31:476-481.
17. Falkenstein I.A., Cheng L., Wong-Staal F., Tammewar A.M., Barron E.C., Silva G.A., Li Q.X., Yu D., Hysell M., Liu G., Ke N., Macdonald J.E., Freeman W.R. Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr. Eye Res. 2008, 33:599-609.
18. Ferris F.L., Fine S.L., Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 1984, 102:1640-1642.
19. Funakoshi T., Birsner A.E., D'Amato R.J. Antiangiogenic effect of oral 2-methoxyestradiol on choroidal neovascularization in mice. Exp. Eye Res. 2006, 83:1102-1107.
20. Hollyfield J.G., Bonilha V.L., Rayborn M.E., Yang X., Shadrach K.G., Lu L., Ufret R.L., Salomon R.G., Perez V.L. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat. Med. 2008, 14:194-198.
21. Hu W., Criswell M.H., Ottlecz A. Oral administration of lumiracoxib reduces choroidal neovascular membrane development in the rat laser-trauma model. Retina 2005, 25(8):1054-1064.
22. Husain D., Kramer M., Kenny A.G., Michaud N., Flotte T.J., Gragoudas E.S., Miller J.W. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7weeks after treatment. Invest. Ophthalmol. Vis. Sci. 1999, 40:2322-2331.
23. Kanai M., Obana A., Gohto Y., Nagata S., Miki T., Kaneda K., Nakajima S. Long-term effectiveness of photodynamic therapy by using a hydrophilic photosensitizer ATX-S10(Na) against experimental choroidal neovascularization in rats. Lasers Surg. Med. 2000, 26:48-57.
24. Kato A., Kimura H., Okabe K., Okabe J., Kunou N., Nozaki M., Ogura Y. Suppression of laser-induced choroidal neovascularization by posterior sub-tenon administration of triamcinolone acetonide. Retina 2005, 25:503-509.
25. Kim S.J., Toma H.S. Inhibition of choroidal neovascularization by intravitreal ketorolac. Arch. Ophthalmol. 2010, 128:596-600.
26. Klein R., Davis M.D., Magli Y.L., Segal P., Klein B.E., Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology 1991, 98:1128-1134.
27. Klein R., Klein B.E., Linton K.L. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992, 99:933-943.
28. Lee E.S., Rewolinski D. Evaluation for CXCR4 inhibition in the prevention and intervention model of laser-induced choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2009, Electronic publication ahead of print.
29. Lu F., Adelman R.A. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247:171-177.
30. Mann A.L., Bressler S.B., Hawkins B.S., Holekamp N., Bressler N.M. Comparison of methods to identify incident cataract in eyes of patients with neovascular maculopathy: Submacular Surgery Trials Report No. 18. Ophthalmology 2008, 115:127-133.
31. Mitchell P., Smith W., Attebo K., Wang J.J. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995, 102:1450-1460.
32. Narasimha-Iyer H., Can A., Roysam B., Stern J. Automated change analysis from fluorescein angiograms for monitoring wet macular degeneration. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2006, 1:4714-4717.
33. Nishiwaki H., Zeimer R., Goldberg M.F., D'Anna S.A., Vinores S.A., Grebe R. Laser targeted photo-occlusion of rat choroidal neovascularization without collateral damage. Photochem. Photobiol. 2002, 75:149-158.
34. Norton E.W., Gass J.D., Smith J.L., Curtin V.T., David N.J., Justice J. Macular diseases: diagnosis. Fluorescein in the study of macular disease. Trans. Am. Acad. Ophthalmol. Otolaryngol. 1965, 69:631-642.
35. Novotny H.R., Alvis D.L. A method of photographing fluorescence in circulating blood in the human retina. Circulation 1961, 24:82-86.
36. Obana A., Gohto Y., Kanai M., Nakajima S., Kaneda K., Miki T. Selective photodynamic effects of the new photosensitizer ATX-S10(Na) on choroidal neovascularization in monkeys. Arch. Ophthalmol. 2000, 118:650-658.
37. Prasad A.G., Van Gelder R.N. Presumed ocular histoplasmosis syndrome. Curr. Opin. Ophthalmol. 2005, 16:364-368.
38. Qu Y., Zhang S., Xu X., Wang H., Li J., Zhou F., Wei F. Octreotide inhibits choroidal neovascularization in rats. Ophthalmic Res. 2009, 42:36-42.
39. Rein D.B., Wittenborn J.S., Zhang X., Honeycutt A.A., Lesesne S.B., Saaddine J. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch. Ophthalmol. 2009, 127:533-540.
40. Sickenberg M., Ballini J.P., van den Bergh H. A computer-based method to quantify the classic pattern of choroidal neovascularization in order to monitor photodynamic therapy. Graefes Arch. Clin. Exp. Ophthalmol. 1999, 237:353-360.
41. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv. Ophthalmol. 2008, 53:121-138.
42. Takahashi K., Saishin Y., Saishin Y., Mori K., Ando A., Yamamoto S., Oshima Y., Nambu H., Melia M.B., Bingaman D.P., Compochiaro P.A. Topical nepafenac inhibits ocular neovascularization. Invest. Ophthalmol. Vis. Sci. 2003, 44(1):409-415.
43. Takahashi H., Yanagi Y., Tamaki Y., Uchida S., Muranaka K. COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model. Biochem. Biophys. Res. Commun. 2004, 325(2):461-466.
44. Tan J.S., Wang J.J., Flood V., Rochtchina E., Smith W., Mitchell P. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2008, 115:334-341.
45. Tatar O., Adam A., Shinoda K., Kaiserling E., Boeyden V., Claes C., Eckardt C., Eckert T., Pertile G., Scharioth G.B., Yoeruek E., Szurman P., Bartz-Schmidt K.U., Grisanti S. Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization. Arch. Ophthalmol. 2009, 127:275-281.
46. Tobe T., Ortega S., Luna J.D., Ozaki H., Okamoto N., Derevjanik N.L., Vinores S.A., Basilico C., Campochiaro P.A. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am. J. Pathol. 1998, 153:1641-1646.
47. Wang F.E., Shi G., Niesman M.R., Rewolinski D.A., Miller S.S. Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye. Exp. Eye Res. 2007, 84:922-933.
48. Yanni S.E., Barnett J.M., Clark M.L., Penn J.S. The role of PGE2 receptor EP4 in pathologic ocular angiogenesis. Invest. Ophthalmol. Vis. Sci. 2009, 50:5479-5486.
49. Yannuzzi L.A., Sorenson J., Spaide R.F., Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990, 10:1-8.
50. Zacks D.N., Ezra E., Terada Y., Michaud N., Connolly E., Gragoudas E.S., Miller J.W. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization. Invest. Ophthalmol. Vis. Sci. 2002, 43:2384-2391.